Gelonghui reported on December 27 that Jinyu Bio-Technology (600201.SH) stated on the interactive platform that the company has formed a joint development team in collaboration with leading figures in the domestic RNA field to create an AI + synthetic biology innovation platform. This initiative aims to preemptively position itself in the fourth generation of vaccines—digital vaccines—gradually establishing a complete system from database construction, AI computing power, vaccine design, animal experimental validation to vaccine registration and industrialization. On one hand, AI deep learning models are utilized to enhance the development and application of animal health products; on the other hand, the massive data generation capabilities of the animal health industry will be leveraged to continually optimize large AI models, digitalizing various indicators at different stages of vaccine research and development.
生物股份(600201.SH)：和国内RNA领域的领军人物合作成立联合开发团队，打造AI+合成生物学创新平台
Jinyu Bio-Technology (600201.SH): Collaborated with leading figures in the domestic RNA field to establish a joint development team, creating an AI + synthetic biology innovation platform.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.